Gossamer Bio, Inc. (GOSS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 3 goss-20260714xex101xrest.htm EX-10.1 goss-20260714xex101xrest GOSSAMER BIO, INC. 2019 INCENTIVE AWARD PLAN (As Amended and Restated Effective May 18, 2026) ARTICLE I. PURPOSE The purpose of this amended and restated Plan is to enhance the Company’s ability to attract, r
How this was made
The 30-second read
Why it matters
Equity-compensation plan restatements can affect future grant practices and dilution over time, but the provided text is mostly administrative plan mechanics.
Market read
Primarily relevant for long-term dilution and governance tracking, with limited immediate trading signal from the excerpt.
What to watch
Traders may want to cross-check the full 8-K exhibits for any specific officer/director appointment terms or quantitative share-pool changes, which are not visible in the provided excerpt.
Background
The SEC 8-K (Item 5.02 and 5.07) indicates director/officer changes and compensatory arrangements tied to an amended and restated 2019 Incentive Award Plan effective May 18, 2026.
Ticker impact
Gossamer Bio filed an 8-K describing amendments to its 2019 Incentive Award Plan and related officer/director compensatory arrangements.
Likely limited near-term impact; any effect would be indirect via dilution expectations or compensation optics.
The filing text is largely plan mechanics (eligibility, share pool, recycling, limits) rather than new guidance, trial results, or capital-structure changes.
Market effects
Minimal; equity-plan amendments are common among biotech issuers and do not, by themselves, change sector fundamentals.
None material indicated.
None material indicated.
Counterpoint
If the amended plan increases flexibility for future grants, it could modestly raise longer-term dilution expectations, but the excerpt provides no grant-size or share-count change beyond generic plan language.
Key entities
- issuerGossamer Bio, Inc.
Subject of the SEC 8-K, filing equity-compensation plan amendments and related compensatory arrangements.
